2016-04-28 13:49:06 UTC

New Clinical Trial Opportunity: Budesonide and EOE

April 27, 2016

The study, which is being led by Shire, is set to finish in July 2018.

A new, phase 3 trial is investigating the effects of the oral steroid budesonide on eosinophilic esophagitis (EoE) in adolescent and adult patients.

The randomized, double-blind trial, led by Shire, is taking place at approximately 60 sites throughout the U.S. and is currently enrolling 300 subjects. Subjects will receive 10 mL of 0.2 mg/mL (2 mg) of the budesonide oral suspension or the placebo every morning and at bedtime over a 16-week treatment period. The study is set to finish in July 2018. 

For more information about the trial or participation in the trial, download the clinical trial overview or visit clinicaltrials.gov (Identifier: NCT02605837).

More on Eosinophilic Esophagitis

Course for APPs benefits all experience levels

April 16, 2018

AGA's popular course for advanced practice providers will take place Aug. 10 through 12 in Chicago, Illinois.

APPs: Enhance your delivery of patient care

March 28, 2018

AGA's popular course for advanced practice providers will be held this summer in Chicago.

Blog: Prick Test to Identify Allergens That Cause Esophageal Sensitization

Jan. 17, 2018

Researchers developed an esophageal prick test, in which the esophageal mucosa is challenged by local injection of allergen extracts. Read more on the AGA Journals Blog.